Deepak Nath

Smith & Nephew has historically underperformed its orthopedic peers (Stryker, Zimmer Biomet, DePuy/J&J) in growth and execution, leading to periods of activist investor pressure and CEO changes. The new leadership is focused on a 12-point operational improvement plan targeting commercial execution, innovation acceleration, and margin expansion. The orthopedic market benefits from powerful demographic tailwinds: aging populations globally drive increasing demand for hip and knee replacements, sports medicine procedures grow as active lifestyles extend into older age groups, and wound care demand rises with diabetes prevalence (diabetic wounds are a major market). Key stock drivers include orthopedic procedure volumes, market share trends versus Stryker and Zimmer, sports medicine innovation, wound care growth, operating margin improvement, China volume-based procurement impact, and the execution of the turnaround plan.